Work

Impact of Prior Treatment on the Efficacy of Tabelecleucel for Epstein–Barr Virus-Driven Posttransplant Lymphoproliferative Disease: Subgroup Analysis from the phase 3 Allele Study

Year: 2026

Type: article

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.jtct.2025.12.207

Authors: Prof. Amer M. Beitinjaneh, Sarah Nikiforow, Kris Michael Mahadeo, Sridhar Chaganti, Sylvain Choquet, Daan Derickx, Armin Ghobadi, Roberta Valenti, Anke Friedetzky, Sandrine Roye, Ran Reshef, Susan E. Prockop, Robert Baiocchi

Institutions: University of Miami Hospital, Sylvester Comprehensive Cancer Center, Harvard University, Dana-Farber Cancer Institute, Duke University, University Hospitals Birmingham NHS Foundation Trust, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Universitair Ziekenhuis Leuven, Washington University in St. Louis, Pierre Fabre (France), Institut de Recherche Pierre Fabre (France), Herbert Irving Comprehensive Cancer Center, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, The Ohio State University

Language: English

Topic: Viral-associated cancers and disorders

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7127408429

FWCI:

Cites:

Cited by:

Related to: 10